Vivaswath S. Ayyar

发表

Modeling Corticosteroid Pharmacogenomics and Proteomics in Rat Liver

D. DuBois, R. Almon, W. Jusko, 2018, The Journal of Pharmacology and Experimental Therapeutics.

Seeking Nonspecific Binding: Assessing the Reliability of Tissue Dilutions for Calculating Fraction Unbound

W. Jusko, Vivaswath S. Ayyar, Emilie A G Molins, 2020, Drug Metabolism and Disposition.

Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics, Part I: Determination and Prediction of Dexamethasone and Methylprednisolone Tissue Binding in the Rat

D. DuBois, R. Almon, W. Jusko, 2019, The Journal of Pharmacology and Experimental Therapeutics.

Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids

W. Jusko, Vivaswath S. Ayyar, 2020, Pharmacological Reviews.

Variability in Zucker diabetic fatty rats: differences in disease progression in hyperglycemic and normoglycemic animals

D. DuBois, R. Almon, W. Jusko, 2014, Diabetes, metabolic syndrome and obesity : targets and therapy.

Minimal Physiologically-Based Pharmacokinetic (mPBPK) Metamodeling of Target Engagement in Skin Informs Anti-IL17A Drug Development in Psoriasis

Weirong Wang, A. Vermeulen, Vivaswath S. Ayyar, 2022, Frontiers in Pharmacology.

Translational PK/PD and model‐informed development of JNJ‐67842125, a Fab reversal agent for JNJ‐64179375, a long‐acting thrombin inhibitor

Brian J. Geist, M. Chintala, Weirong Wang, 2021, British journal of pharmacology.

Pharmacokinetic and Pharmacodynamic Modeling of siRNA Therapeutics – a Minireview

A. Mitra, Vivaswath S. Ayyar, Jae Yoon Jeon, 2022, Pharmaceutical Research.

Indirect pharmacodynamic models for responses with circadian removal

W. Jusko, Vivaswath S. Ayyar, W. Krzyzanski, 2019, Journal of Pharmacokinetics and Pharmacodynamics.

Model‐Based Cellular Kinetic Analysis of Chimeric Antigen Receptor‐T Cells in Humans

Aman P. Singh, Yanguang Cao, Songmao Zheng, 2020, medRxiv.

Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics, Part III: Estrous Cycle and Estrogen Receptor–Dependent Antagonism of Glucocorticoid-Induced Leucine Zipper (GILZ) Enhancement by Corticosteroids

D. DuBois, R. Almon, W. Jusko, 2019, The Journal of Pharmacology and Experimental Therapeutics.

Circadian rhythms: influence on physiology, pharmacology, and therapeutic interventions

S. Sukumaran, Vivaswath S. Ayyar, 2021, Journal of Pharmacokinetics and Pharmacodynamics.

Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics, Part II: Sex Differences in Methylprednisolone Pharmacokinetics and Corticosterone Suppression

D. DuBois, R. Almon, W. Jusko, 2019, The Journal of Pharmacology and Experimental Therapeutics.

Receptor/gene/protein-mediated signaling connects methylprednisolone exposure to metabolic and immune-related pharmacodynamic actions in liver

D. DuBois, R. Almon, W. Jusko, 2018, Journal of Pharmacokinetics and Pharmacodynamics.

Mechanistic Multi—Tissue Modeling of Glucocorticoid-Induced Leucine Zipper Regulation: Integrating Circadian Gene Expression with Receptor-Mediated Corticosteroid Pharmacodynamics

D. DuBois, R. Almon, W. Jusko, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Functional proteomic analysis of corticosteroid pharmacodynamics in rat liver: Relationship to hepatic stress, signaling, energy regulation, and drug metabolism.

D. DuBois, R. Almon, W. Jusko, 2017, Journal of proteomics.

Mechanistic Multi-Tissue Modeling of GILZ Regulation : Integrating Circadian Gene Expression with Receptor-Mediated Corticosteroid Pharmacodynamics

D. DuBois, R. Almon, W. Jusko, 2017 .

CPT: Pharmacometrics & Systems Pharmacology – Inception, Maturation, and Future Vision

E. Sobie, V. Sinha, K. Rowland Yeo, 2021, CPT: pharmacometrics & systems pharmacology.

Quantitative tissue-specific dynamics of in vivo GILZ mRNA expression and regulation by endogenous and exogenous glucocorticoids

D. DuBois, R. Almon, W. Jusko, 2015, Physiological reports.

Receptor/gene/protein-mediated signaling connects methylprednisolone exposure to metabolic and immune-related pharmacodynamic actions in liver

D. DuBois, R. Almon, W. Jusko, 2018, Journal of Pharmacokinetics and Pharmacodynamics.

Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of N-Acetylgalactosamine–Conjugated Small Interfering RNA Disposition and Gene Silencing in Preclinical Species and Humans

Songmao Zheng, D. Heald, Vivaswath S. Ayyar, 2021, The Journal of Pharmacology and Experimental Therapeutics.

ATLAS mPBPK: A MATLAB‐Based Tool for Modeling and Simulation of Minimal Physiologically‐Based Pharmacokinetic Models

William J Jusko, Panteleimon D Mavroudis, Vivaswath S Ayyar, 2019, CPT: pharmacometrics & systems pharmacology.

Pharmacodynamic models of indirect effects and irreversible inactivation with turnover: applicability to mechanism-based modeling of gene silencing and targeted protein degradation.

Vivaswath S. Ayyar, Angelia F. Wang, 2023, Journal of pharmaceutical sciences.

Mechanistic pharmacokinetics and pharmacodynamics of GalNAc-siRNA: Translational model involving competitive receptor-mediated disposition and RISC-dependent gene silencing applied to givosiran

Vivaswath S. Ayyar, Dawei Song, 2023, Journal of Pharmaceutical Sciences.

Indirect pharmacodynamic models for responses with circadian removal

W. Jusko, Vivaswath S. Ayyar, W. Krzyzanski, 2019, Journal of Pharmacokinetics and Pharmacodynamics.